AU2014292355B2 - Targeting of cytokine antagonists - Google Patents
Targeting of cytokine antagonists Download PDFInfo
- Publication number
- AU2014292355B2 AU2014292355B2 AU2014292355A AU2014292355A AU2014292355B2 AU 2014292355 B2 AU2014292355 B2 AU 2014292355B2 AU 2014292355 A AU2014292355 A AU 2014292355A AU 2014292355 A AU2014292355 A AU 2014292355A AU 2014292355 B2 AU2014292355 B2 AU 2014292355B2
- Authority
- AU
- Australia
- Prior art keywords
- fusion protein
- cells
- antagonist
- protein according
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306045 | 2013-07-19 | ||
| EP13306045.9 | 2013-07-19 | ||
| PCT/EP2014/063976 WO2015007520A1 (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014292355A1 AU2014292355A1 (en) | 2016-02-04 |
| AU2014292355B2 true AU2014292355B2 (en) | 2019-08-01 |
Family
ID=48874233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014292355A Active AU2014292355B2 (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9732135B2 (enExample) |
| EP (1) | EP3022230B1 (enExample) |
| JP (1) | JP6475712B2 (enExample) |
| KR (1) | KR102305608B1 (enExample) |
| CN (1) | CN105658669A (enExample) |
| AU (1) | AU2014292355B2 (enExample) |
| CA (1) | CA2918119C (enExample) |
| IL (1) | IL243459B (enExample) |
| MX (1) | MX375426B (enExample) |
| SG (2) | SG11201600165WA (enExample) |
| WO (1) | WO2015007520A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013211059B8 (en) * | 2012-01-20 | 2017-12-21 | Centre Hospitalier Regional Universitaire De Montpellier | Targeted mutant alpha-helical bundle cytokines |
| US9732135B2 (en) * | 2013-07-19 | 2017-08-15 | Vib Vzw | Targeting of human interferon antagonists |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| EP4276114A3 (en) | 2016-03-07 | 2024-02-21 | Vib Vzw | Cd20 binding single domain antibodies |
| US20190077871A1 (en) * | 2016-03-07 | 2019-03-14 | Vib Vzm | Cd20 binding agents and uses thereof |
| US11236141B2 (en) | 2016-05-13 | 2022-02-01 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
| US11753463B2 (en) | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
| JP7204643B2 (ja) | 2016-10-24 | 2023-01-16 | オリオニス バイオサイエンシズ ビーブイ | 標的変異インターフェロン－ガンマおよびその使用 |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| WO2018146074A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| WO2019032661A1 (en) * | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | CD8 LIAISON AGENTS |
| JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| BR112020002706A2 (pt) | 2017-08-09 | 2020-08-25 | Orionis Biosciences Inc. | agentes de ligação a clec9a e uso dos mesmos |
| WO2019148089A1 (en) | 2018-01-26 | 2019-08-01 | Orionis Biosciences Inc. | Xcr1 binding agents and uses thereof |
| CN112074267B (zh) | 2018-02-05 | 2024-06-28 | 奥里尼斯生物科学公司股份有限公司 | 成纤维细胞结合剂及其用途 |
| US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
| CA3118892A1 (en) | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| CN111499718B (zh) * | 2019-01-30 | 2022-06-14 | 复旦大学 | 人α干扰素受体结合相关位点突变体及其用途 |
| JP7773372B2 (ja) | 2019-03-28 | 2025-11-19 | オリオニス バイオサイエンシズ，インコーポレイテッド | 線維芽細胞活性化タンパク質結合物質およびその使用 |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| US12544426B2 (en) | 2019-06-19 | 2026-02-10 | Orionis Biosciences, Inc. | Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes |
| AU2020312735A1 (en) | 2019-07-18 | 2021-12-16 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| JP2024511465A (ja) | 2021-03-26 | 2024-03-13 | イナート・ファルマ・ソシエテ・アノニム | Ｎｋ細胞エンゲージングのためにサイトカインに融合したｎｋｐ４６結合性部位、がん抗原結合性部位を含む多特異性タンパク質 |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| MX2023014647A (es) | 2021-06-09 | 2024-01-31 | Innate Pharma | Proteinas de union a nkp46 multiespecificas. |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
| US20240376229A1 (en) | 2023-05-12 | 2024-11-14 | Regeneron Pharmaceuticals, Inc. | Interferon receptor antagonists and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110224407A1 (en) * | 2008-09-09 | 2011-09-15 | University Of Medicine And Dentistry Of New Jersey | Type I Interferon Antagonists |
| WO2013107791A1 (en) * | 2012-01-20 | 2013-07-25 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3115318B2 (ja) | 1989-08-22 | 2000-12-04 | イミュネックス・コーポレーション | Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質 |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| US6001973A (en) * | 1996-04-26 | 1999-12-14 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
| BR0013231A (pt) * | 1999-08-09 | 2002-07-23 | Lexigen Pharm Corp | Complexos citocina-anticorpo múltiplos |
| US20020193569A1 (en) | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| JP5208733B2 (ja) | 2005-06-29 | 2013-06-12 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 組換えインターフェロンα２（ＩＦＮα２）変異体 |
| CA2693326A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Gm-csf and il-15 fusokines and methods for modulation of the immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| DK2160401T3 (da) * | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| EP2173377B1 (en) | 2007-06-26 | 2017-11-29 | University of Miami | Antibody-endostatin fusion protein and its variants |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| WO2010036918A2 (en) | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
| CA2749558C (en) | 2008-12-08 | 2019-01-15 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| PE20120630A1 (es) | 2009-08-17 | 2012-05-26 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| JP2013504539A (ja) | 2009-09-10 | 2013-02-07 | サイトス バイオテクノロジー アーゲー | 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用 |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| WO2013059885A2 (en) * | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
| CA2866126A1 (en) | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| US9732135B2 (en) * | 2013-07-19 | 2017-08-15 | Vib Vzw | Targeting of human interferon antagonists |
-
2014
- 2014-07-01 US US14/905,348 patent/US9732135B2/en active Active
- 2014-07-01 EP EP14734166.3A patent/EP3022230B1/en active Active
- 2014-07-01 KR KR1020167002677A patent/KR102305608B1/ko active Active
- 2014-07-01 SG SG11201600165WA patent/SG11201600165WA/en unknown
- 2014-07-01 SG SG10202010429YA patent/SG10202010429YA/en unknown
- 2014-07-01 AU AU2014292355A patent/AU2014292355B2/en active Active
- 2014-07-01 CA CA2918119A patent/CA2918119C/en active Active
- 2014-07-01 MX MX2016000721A patent/MX375426B/es active IP Right Grant
- 2014-07-01 JP JP2016526507A patent/JP6475712B2/ja active Active
- 2014-07-01 WO PCT/EP2014/063976 patent/WO2015007520A1/en not_active Ceased
- 2014-07-01 CN CN201480040656.4A patent/CN105658669A/zh active Pending
-
2016
- 2016-01-04 IL IL24345916A patent/IL243459B/en active IP Right Grant
-
2017
- 2017-07-06 US US15/642,989 patent/US10072059B2/en active Active
-
2018
- 2018-06-14 US US16/008,686 patent/US10947288B2/en active Active
- 2018-06-14 US US16/008,695 patent/US20180334489A1/en not_active Abandoned
-
2021
- 2021-02-09 US US17/171,433 patent/US20210238247A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110224407A1 (en) * | 2008-09-09 | 2011-09-15 | University Of Medicine And Dentistry Of New Jersey | Type I Interferon Antagonists |
| WO2013107791A1 (en) * | 2012-01-20 | 2013-07-25 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
| US20140348789A1 (en) * | 2012-01-20 | 2014-11-27 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2918119C (en) | 2022-11-29 |
| SG10202010429YA (en) | 2020-11-27 |
| AU2014292355A1 (en) | 2016-02-04 |
| SG11201600165WA (en) | 2016-02-26 |
| US20180057555A1 (en) | 2018-03-01 |
| WO2015007520A1 (en) | 2015-01-22 |
| KR20160108292A (ko) | 2016-09-19 |
| JP2016529232A (ja) | 2016-09-23 |
| US10072059B2 (en) | 2018-09-11 |
| US20180334488A1 (en) | 2018-11-22 |
| US20180334489A1 (en) | 2018-11-22 |
| US9732135B2 (en) | 2017-08-15 |
| MX375426B (es) | 2025-03-06 |
| US20210238247A1 (en) | 2021-08-05 |
| CA2918119A1 (en) | 2015-01-22 |
| EP3022230A1 (en) | 2016-05-25 |
| US20160159875A1 (en) | 2016-06-09 |
| EP3022230B1 (en) | 2019-11-06 |
| KR102305608B1 (ko) | 2021-09-28 |
| IL243459A0 (en) | 2016-03-31 |
| JP6475712B2 (ja) | 2019-02-27 |
| IL243459B (en) | 2019-10-31 |
| MX2016000721A (es) | 2016-09-07 |
| CN105658669A (zh) | 2016-06-08 |
| US10947288B2 (en) | 2021-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10947288B2 (en) | Targeting of human interferon antagonists | |
| Bernstein et al. | Engineering the IL‐4/IL‐13 axis for targeted immune modulation | |
| Larochette et al. | IL-26, a cytokine with roles in extracellular DNA-induced inflammation and microbial defense | |
| Zhou et al. | Interleukin-36: structure, signaling and function | |
| Conti et al. | IL-17 receptor signaling in oral epithelial cells is critical for protection against oropharyngeal candidiasis | |
| Whibley et al. | Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis | |
| Campanella et al. | CXCL10 can inhibit endothelial cell proliferation independently of CXCR3 | |
| Wang et al. | Interleukin-18 and IL-18BP in inflammatory dermatological diseases | |
| AU2013211059B8 (en) | Targeted mutant alpha-helical bundle cytokines | |
| Sasaoka et al. | Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells | |
| Doodes et al. | IFN-γ regulates the requirement for IL-17 in proteoglycan-induced arthritis | |
| US20210395376A1 (en) | Antibodies and polypeptides directed against cd127 | |
| JP2009543579A (ja) | 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８ | |
| CA2903359A1 (en) | Targeted modulation of macrophages | |
| Martinez-Martinez et al. | A novel gain-of-function STAT1 mutation resulting in basal phosphorylation of STAT1 and increased distal IFN-γ-mediated responses in chronic mucocutaneous candidiasis | |
| WO2005079848A2 (en) | Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders | |
| US20230303680A1 (en) | A cd25-biased anti-il-2 antibody | |
| Class et al. | Patent application title: TARGETING OF CYTOKINE ANTAGONISTS | |
| HK1225047A1 (en) | Targeting of cytokine antagonists | |
| HK1225047B (en) | Targeting of Cytokine Antagonists | |
| BR112016001122B1 (pt) | Proteína de fusão compreendendo um antagonista de interferon e uma fração de direcionamento | |
| US20260132191A1 (en) | Methods for modulating activity of il-18 for treatment of cd4+ t cell mediated autoimmunity and immunopathology | |
| Skouris | Investigating the action mechanisms of IL-12 and IL-23 in an experimental model of Crohn’s disease | |
| Class et al. | Patent application title: TARGETED MUTANT ALPHA-HELICAL BUNDLE CYTOKINES Inventors: Jan Tavernier (Balegem, BE) Jan Tavernier (Balegem, BE) Gilles Uze (Montpellier, FR) Guillaume Cartron (Combaillaux, FR) Franciane Paul (Montpellier, FR) Jacob Piehler (Osnabruck, DE) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTP Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2 Owner name: UNIVERSITE DE MONTPELLIER Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2 Owner name: VIB VZW Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2 Owner name: UNIVERSITEIT GENT Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2 Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2 |
|
| FGA | Letters patent sealed or granted (standard patent) |